New study shows bimekizumab, a dual IL-17 inhibitor, improves symptoms in 47.7% of non-radiographic axSpA & 44.8% of radiographic axSpA patients. Results from phase 3 trials show significant & rapid improvement in primary & secondary endpoints
318 followers
8,532 followers
BIM -bi-specific MoAb is potent xcross IMIDS NOW is time to sort out fungal infections appear mild/mod-need more data &strategies @PaulSaxMD Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 controlled tria
150 followers
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials https://t.co/OZfkU6F2EV